Related Experiment Video
Updated: Mar 6, 2026

Serum and Plasma Copy Number Detection Using Real-time PCR
Published on: December 15, 2017
Contrasting roles of the ABCG2 Q141K variant in prostate cancer
Kathryn M Sobek1, Jessica L Cummings2, Dean J Bacich3
1Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Abstract:
ABCG2 is a membrane transport protein that effluxes growth-promoting molecules, such as folates and dihydrotestosterone, as well as chemotherapeutic agents. Therefore it is important to determine how variants of ABCG2 affect the transporter function in order to determine whether modified treatment regimens may be necessary for patients harboring ABCG2 variants. Previous studies have demonstrated an association between the ABCG2 Q141K variant and overall survival after a prostate cancer diagnosis. We report here that in patients with recurrent prostate cancer, those who carry the ABCG2 Q141K variant had a significantly shorter time to PSA recurrence post-prostatectomy than patients homozygous for wild-type ABCG2 (P=0.01). Transport studies showed that wild-type ABCG2 was able to efflux more folic acid than the Q141K variant (P<0.002), suggesting that retained tumoral folate contributes to the decreased time to PSA recurrence in the Q141K variant patients. In a seemingly conflicting study, it was previously reported that docetaxel-treated Q141K variant prostate cancer patients have a longer survival time. We found this may be due to less efficient docetaxel efflux in cells with the Q141K variant versus wild-type ABCG2. In human prostate cancer tissues, confocal microscopy revealed that all genotypes had a mixture of cytoplasmic and plasma membrane staining, with noticeably less staining in the two homozygous KK patients. In conclusion, the Q141K variant plays contrasting roles in prostate cancer: 1) by decreasing folate efflux, increased intracellular folate levels result in enhanced tumor cell proliferation and therefore time to recurrence decreases; and 2) in patients treated with docetaxel, by decreasing its efflux, intratumoral docetaxel levels and tumor cell drug sensitivity increase and therefore patient survival time increases. Taken together, these data suggest that a patient's ABCG2 genotype may be important when determining a personalized treatment plan.
Insights
The ABCG2 Q141K variant impacts prostate cancer recurrence and survival. This variant reduces folate efflux, accelerating recurrence, but also decreases docetaxel efflux, improving survival in treated patients, suggesting genotype-guided treatment.
Area of Science:
- Oncology
- Pharmacogenomics
- Molecular Biology
Background:
- ABCG2 is a membrane transporter affecting drug and molecule efflux.
- The ABCG2 Q141K variant is linked to prostate cancer outcomes.
- Understanding ABCG2 variant function is crucial for personalized treatment.
Purpose of the Study:
- To investigate the functional impact of the ABCG2 Q141K variant on prostate cancer.
- To correlate ABCG2 genotype with time to PSA recurrence and survival.
- To elucidate the mechanisms behind the variant's contrasting effects on tumor growth and drug response.
Main Methods:
- Analysis of PSA recurrence in prostate cancer patients with different ABCG2 genotypes.
- In vitro transport assays measuring folic acid and docetaxel efflux.
- Confocal microscopy of ABCG2 expression in human prostate cancer tissues.
Main Results:
- The ABCG2 Q141K variant was associated with a shorter time to PSA recurrence.
- Q141K variant showed reduced folic acid efflux compared to wild-type.
- Q141K variant exhibited less efficient docetaxel efflux, potentially increasing drug sensitivity.
Conclusions:
- The ABCG2 Q141K variant has dual roles in prostate cancer, influencing recurrence and treatment response.
- Decreased folate efflux by Q141K enhances proliferation and shortens recurrence time.
- Reduced docetaxel efflux by Q141K may improve survival in treated patients.
- ABCG2 genotype may guide personalized prostate cancer treatment strategies.
More Related Videos
Related Concept Videos
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The Ras Gene
Ras is a...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

